A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their waist compared with Novo Nordisk’s rival Wegovy. At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head trial of the blockbuster weight-loss medications.

Landmark research suggests the appetite-suppressing jabs which mimic a hormone that makes us feel full also significantly cut cancer risk by lowering inflammation